Tobi is responsible for the clinical development of the drugs in Ellipses’ pipeline. He leads clinical strategy, coordinates the drug development teams to deliver the clinical programmes and is an ambassador for our Scientific Affairs Group.

Over the course of his career, Tobi has worked on over 300 early-stage clinical trials, with several of these trials providing the compounds that have gone on to become the new standard of care.

A Medical Oncologist by training, Tobi is a practicing clinician having begun his early career as an oncologist in Bremen, Germany and then at the Royal Marsden Hospital in London, before becoming a team leader in Clinical Drug Development at the University of New South Wales, Australia. He has

spent over a decade as a Professor at University College London, and most recently was the Executive Medical Director at the Sarah Cannon Research Institute. He holds a PhD from the Medical School of Hanover.

David has been Chief Financial Officer at Ellipses since its early stages and is also a Director on its Board.

As a central member of the executive team, he drives the company’s growth and helps to set its strategy, as well as taking on key responsibilities in funding and business development.

David has extensive experience as a CFO within the life sciences industry. He began his career at PricewaterhouseCoopers where he qualified as a chartered accountant, before holding CFO and Group Financial Controller positions at several life sciences companies. A personal highlight was his steering of Biotie Therapies through its listing on NASDAQ, as its CFO. More recently, he has served on the board of AIM-listed Alliance Pharmaceuticals, including currently as its Non-Executive Chairman.

David holds a degree in Chemistry from the University of Oxford.

Martin is an expert in drug development and manufacturing and has played a pivotal role in bringing thirteen drugs to market to date. His broad experience across the pharmaceutical industry started within big pharma at Aventis, includes eight years at Shire Pharmaceuticals, where he was a Senior Director of Product Development, and more recently as Global Head of Product Development and Manufacturing at HUYA Bioscience.

At Ellipses, Martin leads the non-clinical and preclinical development arms of the organisation, working in conjunction with the clinical development arm to progress Ellipses’ exciting portfolio of oncology assets.

Martin graduated with a degree in Applied and Analytical Chemistry from Staffordshire University and has a post-graduate certificate in management studies.

Nicky has 15 years’ deal experience in the life-sciences and pharmaceutical industry with companies including GlaxoSmithKline, Speciality Pharma and GE Healthcare Life Sciences. At Ellipses, Nicky is responsible for in-licensing new assets to the company’s development pipeline, as well as their subsequent out-licensing.

Nicky has led multiple transactions including company and product acquisitions, and product divestments across all phases of drug development.

Nicky has a biochemistry degree and a PhD in drug delivery from University College London.

Suzanne is responsible for driving the Ellipses company ethos, culture and enriching the work experience of the team. She joined Ellipses early in its inception and has worked to create a pioneering and entrepreneurial culture in which employees can achieve and thrive, alongside the focused hiring of talent to spur Ellipses forward in its mission of developing cancer drugs at pace.

Previously, Suzanne was HR Director (UK) and Director of Organisational Development, Europe, at Pfizer and HR and Communications Director at Basilea Pharmaceutica. She has served as a as a non-executive director at the Royal Surrey NHS Foundation Trust, where she was part of the team that drove its transition to Foundation Trust status. She holds a degree in Medieval, Modern and American History from the University of Hull.

Sarah is an experienced pharmaceutical lawyer with two decades of expertise in the full lifecycle of a pharmaceutical product including in-licensing, asset sales, marketing and communications, competition law, employment and corporate transactions. She currently also holds the position of Company Secretary at Ellipses. Having started her legal career at a private law firm, Sarah has worked with Roche, AstraZeneca, Medimmune, MSD and BioFocus, a Galapagos affiliate. Sarah leads the legal and IP team at Ellipses, focusing on corporate governance, strategic transactions and compliance.

Luke has over 20 years of experience in the life sciences industry spanning operations, digital, data and business transformation. At Ellipses, he leads company-wide strategy planning and performance reporting, helping to translate strategy into execution and align organisational priorities with business objectives. He also oversees business operations, technology and cross-functional initiatives, and has been instrumental in building the operational capabilities, digital platforms and data-driven approach that supports the company’s growth.

Before joining Ellipses, Luke was Head of IT, Europe and Asia (R&D), at Takeda Pharmaceuticals, where he supported the organisation’s expansion into Asia and China. He also played a key role in the creation of CSL Seqirus following the acquisition of Novartis’ influenza division and the divestment of CSL Behring’s influenza business.

Carol is a research professional with a 25+ year career across the pharmaceutical, biotechnology and CRO sectors, with extensive experience in early phase oncology drug development. At Ellipses, she leads the Clinical Operations team in the execution of the clinical trial programme for our portfolio.  Previous roles include VP, Head of Global Clinical Operations at Avacta, Head of European Clinical Operation, Antisoma Research and Senior Director at the Sarah Cannon Development Innovations.

Carol has a BSc (1st Class) in Pharmacology from the University of Glasgow and a PhD in Cardiovascular Pharmacology from the University of Strathclyde.